OCUP
Ocuphire Pharma, Inc.
2.98
USD
This page is just a preview of the data found in TrendSpider’s full version
Ocuphire Pharma, Inc. stock is up 8.76% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45% of the previous 19 December’s closed higher than November. 100% of analysts rate it a buy.
Ocuphire Pharma, Inc. focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, which is in Phase III clinical trial for dim light or night vision disturbances. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases.
